Tag Archives: Michael Matson

Needham Reaffirms Their Buy Rating on Hill-Rom (HRC)

Needham analyst Michael Matson reiterated a Buy rating on Hill-Rom (HRC – Research Report) today and set a price target of $131.00. The company’s shares closed last Monday at $109.89. According to TipRanks.com, Matson is a 5-star analyst with an

Atricure (ATRC) Gets a Buy Rating from Needham

Needham analyst Michael Matson reiterated a Buy rating on Atricure (ATRC – Research Report) today and set a price target of $48.00. The company’s shares closed last Monday at $37.50, close to its 52-week high of $39.25. According to TipRanks.com,

Needham Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)

Needham analyst Michael Matson maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) today and set a price target of $187.00. The company’s shares closed last Monday at $148.88, close to its 52-week high of $150.79. According

Needham Keeps a Buy Rating on Cantel Medical (CMD)

In a report released today, Michael Matson from Needham maintained a Buy rating on Cantel Medical (CMD – Research Report), with a price target of $94.00. The company’s shares closed last Monday at $72.99. According to TipRanks.com, Matson is a

Conmed (CNMD) was Downgraded to a Hold Rating at Needham

Needham analyst Michael Matson downgraded Conmed (CNMD – Research Report) to Hold today. The company’s shares closed last Monday at $116.55, close to its 52-week high of $116.81. According to TipRanks.com, Matson is a 5-star analyst with an average return

Analysts Offer Insights on Healthcare Companies: Cantel Medical (NYSE: CMD) and Global Blood Therapeutics (NASDAQ: GBT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cantel Medical (CMD – Research Report) and Global Blood Therapeutics (GBT – Research Report) with bullish sentiments. Cantel Medical (CMD) Cantel Medical